Page 343 of 441: studies 3,421 to 3,430 of 4,401, newest first. Back to the psilocybin overview
OPAL (Open@LaTrobe) (La Trobe University) May 7, 2025
Background: Opioid use disorder (OUD) is a debilitating health condition that is associated with significant morbidity and mortality in the U.S. While preliminary studies have demonstrated that psilocybin is associated with lowered odds of OUD, current research in this domain suffers from a lack of investigation into the impact of race/ethnicity on this association. Objective: To assess the...
OPAL (Open@LaTrobe) (La Trobe University) May 7, 2025
Background: Opioid use disorder (OUD) is a debilitating health condition that is associated with significant morbidity and mortality in the U.S. While preliminary studies have demonstrated that psilocybin is associated with lowered odds of OUD, current research in this domain suffers from a lack of investigation into the impact of race/ethnicity on this association. Objective: To assess the...
Psychedelics May 6, 2025 Michael A. Wheeler
In a thought-provoking Genomic Press interview, Dr. Michael Wheeler emerges as a brilliant scientific innovator at the intersection of neuroscience and immunology. As an Assistant Professor at Harvard Medical School and an investigator at Brigham and Women's Hospital, Wheeler's groundbreaking research explores how brain-immune communication shapes our behaviors and emotions. His innovative...
ChemBioChem May 3, 2025 Nick Zschoche, Markus Gressler, Stefan Bartram et al. 1 citation
Psilocybe “magic mushrooms” are best known for their indolethylamine psilocybin, yet they encode enzymes for a much more diverse arsenal of small and potentially bioactive molecules. Herein, four Psilocybe cubensis clade III sesquiterpene synthases, CubB‐CubE, whose genes are differently expressed in fruiting bodies compared to vegetative mycelium are reported. CubB‐CubE were functionally...
Alcoholism Treatment Quarterly May 2, 2025 Ritika Shah, Ashish Sarangi
ABSTRACT Background Alcohol Use Disorder (AUD) is a widespread condition with serious health, social, and economic impacts, often marked by relapse despite the availability of FDA-approved treatments. Recent studies suggest that psychedelic substances, such as psilocybin, Lysergic acid diethylamide (LSD), ayahuasca, etc. may offer novel therapeutic potential in treating AUD by modulating...
Journal of Medicinal Chemistry May 1, 2025 Saghir Ali, Xiaochen Tian, Kathryn A. Cunningham et al. 5 citations
Targeting the 5-HT2A Receptor for Developing Psychedelic Drugs and Beyond.
Sleep May 1, 2025 Denise C. Vidot, Amrit Baral, Bria-Necole Diggs et al.
Abstract Introduction Research on psychedelic use and sleep satisfaction remains unclear despite increased use. This study examines the psychedelic use and sleep satisfaction among 18-to-35-year-olds enrolled in the Herbal Heart Study. Methods The exposure variables were lifetime self-reported use of any psychedelic (LSD, psilocybin, peyote, mescaline, ayahuasca/DMT) and psilocybin-alone. Sleep...
Neuropharmacology May 1, 2025 Michael Noback, Johnny A Kenton, Adam K. Klein et al. 2 citations
Treating amotivated states remains difficult. Classical psychedelic drugs (5-HT2A receptor agonists) such as LSD and psilocybin have shown therapeutic potential in treating such symptoms, but their development has been hindered by their undesirable hallucinogenic effects. There is increasing evidence that administration of psychedelics at dose levels too low to evoke a hallucinogenic effect...
American Journal of Public Health May 1, 2025 Karilynn M Rockhill, Joshua C. Black, Janetta Iwanicki et al. 17 citations
Objectives. To characterize present-day polysubstance use patterns in the general adult population. Methods. From a 2022 nationally representative survey in the United States, we defined polysubstance use as last 12-month use of 2 or more drugs (n = 15 800). Latent class analyses included medical (as indicated) and nonmedical (not as directed) use of prescription opioids, stimulants,...
Drugs May 1, 2025 Sharmin Ghaznavi, Sarah G Richter 6 citations
There has been a recent resurgence in research on psychedelics as therapeutic agents for psychiatric conditions. This leading article outlines the studies to date of classic psychedelic treatments for treatment-resistant depression and major depression, including psilocybin, ayahuasca, dimethyltryptamine (DMT), and O-methyl-bufotenine (5-Me-O DMT). We discuss the potential of expanding...